The deal will allow Novavax to lift its "going concern" warning, which it first issued in 2023 due to having "substantial ...
Novavax (NVAX) stock surged after reaching a licensing agreement with Sanofi (SNY) for its COVID-19 vaccine and Matrix-M adjuvant. Read more here.
(Reuters) -Hedge fund Shah Capital said on Monday it would withdraw its campaign against the re-election of three directors ...
Shah Capital Management has withdrawn a proxy campaign against the re-election of directors at vaccines firm Novavax in the ...
A Novavax shareholder that had been waging a campaign to oust three board members at the Gaithersburg company has now ...
Novavax will only be able to offer a COVID-19 vaccine in the United States this autumn if regulators accept the shot it has ...
Novavax ( NVAX -9.65%) has been a highly volatile stock in recent years, and that volatility is on full display again this ...
He joined the company in mid-2020, at the height of the coronavirus pandemic. The head of research and development at Novavax ...
Sanofi will pay $500 million up front to Novavax for the right to co-commercialize Nuvaxovid worldwide (except in a few ...
The COVID-19 vaccine was worth tens of billions of dollars, but most of it went into the hands of Moderna and Pfizer. Smaller ...
Aventis S.A. ADR (SNY-Q) from The Globe and Mail including charting and trades.
Novavax (NVAX) partners with Sanofi to market its COVID-19 vaccine and also develop novel COVID-19-influenza combination ...